Company News

MIMEDX, INC. - Marietta, GA

Original Press Release

MiMedx Agrees to Lawsuit Settlement with Former Employee

Press release date: Dec 19, 2017

MARIETTA, Ga., Dec. 19, 2017 - MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company has agreed to a confidential lawsuit settlement from one former employee.

MiMedx has reached a mutually agreeable settlement in its lawsuit with former employee, William T. Mills, who voluntarily resigned from MiMedx in January 2017. In its suit, MiMedx alleged that Mills breached his restrictive covenants and his duty of loyalty to MiMedx by selling another company's medical products while employed by MiMedx, and continued to breach his restrictive covenants after he voluntarily left MiMedx's employ. This lawsuit was a dispute solely over Mr. Mills' MiMedx employment agreement, and no other allegations have been made by either party.

In addition to an undisclosed monetary settlement, other settlement terms were reached. In this regard, Mills has agreed not to sell any products of his current employer to any MiMedx customer serviced by Mills for nine months.

Mills also acknowledges and confirms that he made no allegations of "channel stuffing" by MiMedx in this lawsuit. Mills stated, "I have no knowledge of the agreements or payment terms between MiMedx and its customers. I also do not know or have any way of knowing of how sales of products were accounted for by the Company in its financial statements. To my knowledge, the vast majority of the MiMedx products which were sold into my accounts were used and were not returned. MiMedx makes an excellent product. I look forward to continuing my employment with my current employer."

Parker H. "Pete" Petit, CEO, said, "We are pleased to have settled this lawsuit with Mr. Mills. The prosecution of our other lawsuits is critical to ensuring the appropriate legal remedies and to rectify the misconduct committed by those individuals. Mr. Mills did not bring any claims alleging channel stuffing, as other employees have, and he does not have enough knowledge of accounting matters to make such an allegation. We are glad we were able to resolve this matter amicably with Mr. Mills. We look forward to achieving appropriate outcomes from our legal actions against those other individuals."

About MiMedx

MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.